Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group ( (AU:MYX) ) has provided an update.
Mayne Pharma Group has announced that director Frank Charles Condella Jr has ceased to be a director of the company effective 14 January 2026. At the time of his departure, Condella held 65,929 ordinary shares in Mayne Pharma, and the company reported no additional indirect security holdings or contractual interests linked to his role, indicating a straightforward change in board composition without disclosed related-party or contractual complexities.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australian specialty pharmaceutical company that develops, manufactures and markets branded and generic medicines. The company focuses on oral drug delivery technologies and supplies products to markets including Australia and the United States, targeting both retail and hospital channels through its portfolio of specialty and generic pharmaceuticals.
Average Trading Volume: 568,513
Technical Sentiment Signal: Sell
Current Market Cap: A$257.5M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.